To view this email as a web page, click here.

Conference Coverage
 
Coverage from ASRS 2018 Day 1
 
How AMD patients are treated in the ‘real world’
Injection frequency plays a large role in visual acuity outcomes. However, there does seem to be a ceiling effect at 10 injections, says David F. Williams, MD. Why is this?
Read more
ADVERTISEMENT
 
Brolucizumab: Next-generation of anti-VEGF therapy?
Learn how two large, phase III studies—HAWK and HARRIER—are the first that "individualize" treatment, says Pravin U. Dugel, MD.
Read more
 
What APL-2 means for geographic atrophy
In the largest phase II trial evaluating dry AMD to date, the effect of APL-2 was greatest in the second 6 months of treatment. Nathan Steinle, MD, explains why.
Read more
 
RELATED ARTICLES
 
The role of oxidative stress in DME
Pearls for better uveitis workups
The time has come for gene therapy to treat retinal disease, AMD
Dendritic cells migrate to regions of retinal stress, mediate neurodegeneration
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.